Sagora Therapeutics is an early-stage Canadian biotech company focused on identifying and developing new indications for existing FDA-approved compounds in underserved neurological patient populations.
Our drug repurposing strategy leverages the established safety profiles of approved small molecule compounds to accelerate time to clinic. By targeting specific, well-characterized patient populations with clear mechanistic rationale, we reduce development risk while addressing conditions with limited treatment options.
Building on FDA-approved compounds with known tolerability profiles.
Precision focus on specific patient segments with clear unmet need.
Repurposing strategy shortens the development timeline to clinic.
Our lead asset addresses a neurological indication in a defined patient population where current standard of care remains inadequate. The program is supported by a patent-pending novel method of treatment with minimal prior art identified.
Sagora was founded by an experienced innovator with deep knowledge of the target indication, patient population, and regulatory landscape.
Drug repurposing strategy · Neurological indications · IP development · Business development and licensing
Sagora Therapeutics welcomes inquiries from potential licensing partners, clinical collaborators, and investors aligned with our mission to bring novel therapies to underserved patient populations.
info.hadley@gmail.com